Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time.

A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout Acute Coronary Syndrome Acute Kidney Injury Arthritis Cardiovascular Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Crystal Arthropathies Digestive System Diseases Dyspnea Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Gout Heart Diseases Heart Failure Hepatic Insufficiency Joint Diseases Kidney Diseases Liver Diseases Liver Failure Liver Failure, Acute Male Urogenital Diseases Metabolic Diseases Metabolism, Inborn Errors Musculoskeletal Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Pathological Conditions, Signs and Symptoms Purine-Pyrimidine Metabolism, Inborn Errors Renal Insufficiency Respiration Disorders Respiratory Tract Diseases Rheumatic Diseases Signs and Symptoms Signs and Symptoms, Respiratory Urogenital Diseases Urologic Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site

Stockholm, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

First time users of ticagrelor, clopidogrel and prasugrel, respectively

Exclusion criteria

Individuals with more than one of above three antiplatelet drugs dispensed the same day

Treatment and study plan

Risk of selected safety events

Drug

First time users of ticagrelor, clopidogrel and prasugrel, respectively

Primary outcomes

Drug utilization: Description of patient characteristics and drug usage

Time frame: Up to one year after entry into study cohort

Secondary outcomes

Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout

Time frame: Up to one year after entry into study cohort.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Jan 13, 2011
Registry last updated: Mar 31, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed